Abstract
Hodgkin's lymphoma (HL) is the most common malignant lymphoma in young adults in the western world. This disease is characterized by an overexpression of ADAM-10 with increased release of NKG2D ligands, involved in an impaired immune response against tumor cells. We designed and synthesized two new ADAM-10 selective inhibitors, 2 and 3 based on previously published ADAM-17 selective inhibitor 1. The most promising compound was the thiazolidine derivative 3, with nanomolar activity for ADAM-10, high selectivity over ADAM-17 and MMPs and good efficacy in reducing the shedding of NKG2D ligands (MIC-B and ULBP3) in three different HL cell lines at non-toxic doses. Molecular modeling studies were used to drive the design and X-ray crystallography studies were carried out to explain the selectivity of 3 for ADAM-10 over MMPs.
| Original language | English |
|---|---|
| Pages (from-to) | 193-201 |
| Number of pages | 9 |
| Journal | European Journal of Medicinal Chemistry |
| Volume | 111 |
| DOIs | |
| Publication status | Published - Mar 23 2016 |
Fingerprint
Keywords
- ADAM-10 inhibitors
- Hodgkin's lymphoma
- NKG2D-L
- Sulfonamido-based hydroxamates
ASJC Scopus subject areas
- Drug Discovery
- Organic Chemistry
- Pharmacology
Cite this
Discovery of a new selective inhibitor of A Disintegrin and Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin's lymphoma cell models. / Camodeca, Caterina; Nuti, Elisa; Tepshi, Livia; Boero, Silvia; Tuccinardi, Tiziano; Stura, Enrico A.; Poggi, Alessandro; Zocchi, Maria Raffaella; Rossello, Armando.
In: European Journal of Medicinal Chemistry, Vol. 111, 23.03.2016, p. 193-201.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Discovery of a new selective inhibitor of A Disintegrin and Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin's lymphoma cell models
AU - Camodeca, Caterina
AU - Nuti, Elisa
AU - Tepshi, Livia
AU - Boero, Silvia
AU - Tuccinardi, Tiziano
AU - Stura, Enrico A.
AU - Poggi, Alessandro
AU - Zocchi, Maria Raffaella
AU - Rossello, Armando
PY - 2016/3/23
Y1 - 2016/3/23
N2 - Hodgkin's lymphoma (HL) is the most common malignant lymphoma in young adults in the western world. This disease is characterized by an overexpression of ADAM-10 with increased release of NKG2D ligands, involved in an impaired immune response against tumor cells. We designed and synthesized two new ADAM-10 selective inhibitors, 2 and 3 based on previously published ADAM-17 selective inhibitor 1. The most promising compound was the thiazolidine derivative 3, with nanomolar activity for ADAM-10, high selectivity over ADAM-17 and MMPs and good efficacy in reducing the shedding of NKG2D ligands (MIC-B and ULBP3) in three different HL cell lines at non-toxic doses. Molecular modeling studies were used to drive the design and X-ray crystallography studies were carried out to explain the selectivity of 3 for ADAM-10 over MMPs.
AB - Hodgkin's lymphoma (HL) is the most common malignant lymphoma in young adults in the western world. This disease is characterized by an overexpression of ADAM-10 with increased release of NKG2D ligands, involved in an impaired immune response against tumor cells. We designed and synthesized two new ADAM-10 selective inhibitors, 2 and 3 based on previously published ADAM-17 selective inhibitor 1. The most promising compound was the thiazolidine derivative 3, with nanomolar activity for ADAM-10, high selectivity over ADAM-17 and MMPs and good efficacy in reducing the shedding of NKG2D ligands (MIC-B and ULBP3) in three different HL cell lines at non-toxic doses. Molecular modeling studies were used to drive the design and X-ray crystallography studies were carried out to explain the selectivity of 3 for ADAM-10 over MMPs.
KW - ADAM-10 inhibitors
KW - Hodgkin's lymphoma
KW - NKG2D-L
KW - Sulfonamido-based hydroxamates
UR - http://www.scopus.com/inward/record.url?scp=84957547562&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84957547562&partnerID=8YFLogxK
U2 - 10.1016/j.ejmech.2016.01.053
DO - 10.1016/j.ejmech.2016.01.053
M3 - Article
VL - 111
SP - 193
EP - 201
JO - European Journal of Medicinal Chemistry
JF - European Journal of Medicinal Chemistry
SN - 0223-5234
ER -